Abstract 5166: A multiplexed immunofluorescence assay to assess Rb and phospho-Rb as predictive biomarkers for CDK4/6 inhibitors in HR+/HER2- breast cancerMantasha Tabassum, Meghana V. Trivedi, Shivaani Suresh Kanna et al.|Cancer Research|2024Cited by 0
Abstract 2027: Developing an image analysis algorithm to evaluate immunofluorescence intensity for Rb and phospho-Rb expression in circulating tumor cells in HR+/HER2- breast cancerShivaani Suresh Kanna, Meghana V. Trivedi, Mantasha Tabassum|Cancer Research|2025Cited by 0
Abstract 5250: Method development and workflow optimization of a CTC-based biomarker assay to predict response to CDK4/6 inhibitors in HR+/HER2- breast cancerMantasha Tabassum, Meghana V. Trivedi, Mothaffar F. Rimawi et al.|Cancer Research|2026Cited by 0
Abstract 4462: Nebivolol inhibits cell growth, inhibits autophagic flux, and enhances growth inhibition in combination with bicalutamide in prostate cancer cells.Swarnil Mandal, Meghana V. Trivedi, Wangjia Cao et al.|Cancer Research|2026Cited by 0
Abstract 4461: Nebivolol exhibits cell growth inhibition in drug-resistant HR+/HER2- breast cancer and anti-tumoral synergism with abemaciclib <i>in vitro</i> .Chia‐Ling Wu, Shivaani Suresh Kanna, Meghana V. Trivedi|Cancer Research|2026Cited by 0